8-KMaterial Agreements

BIOGEN INC. 8-K Report, Material Agreement (Apr 10, 2006)

Filed April 10, 2006For Securities:BIIB

Summary

This 8-K filing from Biogen Idec Inc. (now Biogen Inc.) reports on compensation matters approved by the company's Board of Directors and its Compensation Committee. On April 4, 2006, the Compensation Committee approved new annual base salaries for two key executives: Dr. Burt A. Adelman, Executive Vice President of Development, was granted a $500,000 base salary, and Dr. Michael D. Kowolenko, Senior Vice President of Pharmaceutical Operations and Technology, received a $390,000 base salary. Additionally, on April 5, 2006, the Board of Directors approved a new compensation arrangement for the Chair of the Transaction Committee. This individual will receive an annual retainer of $10,000, which is separate from their existing compensation as a Board member. These disclosures are standard for material changes in executive compensation and board committee roles, providing transparency to investors regarding executive pay and governance.

Key Highlights

  • 1Approval of $500,000 annual base salary for Burt A. Adelman, MD, Executive Vice President, Development.
  • 2Approval of $390,000 annual base salary for Michael D. Kowolenko, Ph.D., Senior Vice President, Pharmaceutical Operations and Technology.
  • 3Establishment of a $10,000 annual retainer for the Chair of the Transaction Committee of the Board of Directors.
  • 4The Transaction Committee Chair's retainer is in addition to other director compensation.
  • 5The reported compensation changes were approved by the Compensation and Management Development Committee and the Board of Directors on April 4th and 5th, 2006, respectively.
  • 6These adjustments reflect material definitive agreements related to executive and board member compensation.

Frequently Asked Questions

This 8-K filing's primary purpose is to report on material definitive agreements regarding compensation. Specifically, it details the approved annual base salaries for two key executives and a new annual retainer for the Chair of the Board's Transaction Committee.

The filing indicates new annual base salaries were approved for Dr. Burt A. Adelman ($500,000) and Dr. Michael D. Kowolenko ($390,000). Additionally, the Chair of the Transaction Committee of the Board of Directors will receive a $10,000 annual retainer.

The base salaries for Dr. Adelman and Dr. Kowolenko were approved on April 4, 2006, by the Compensation and Management Development Committee. The compensation for the Chair of the Transaction Committee was approved on April 5, 2006, by the Board of Directors.

Yes, the filing explicitly states that the $10,000 annual retainer for the Chair of the Transaction Committee is in addition to other compensation that the Chair receives as a member of the Registrant's Board of Directors.